fr   en
Clinical Studies
Phase :    
Announcement :   
Select a Pharma :
Select a product :
Select a disease :
Choose date:
1   |   2   |   3   |   4   |   5   |   6   |   7   |   8   |   9   |   10   |   11      »      [57]
Date Phase Anouncement Biotech Pharma Product Disease Country Other
2010-09-08 III Launch Genmab (Denmark) GSK (UK) Ofatumumab + bendamustine indolent B-cell non-Hodgkin’s lymphoma   See details
2010-09-07 I-II Result Immutep (France)   IMP321 (recombinant soluble LAG-3Ig fusion protein that binds to MHC class II with high avidity and mediates APC and then antigen-experienced memory CD8+ T cell activation) metastatic breast cancer France See details
2010-09-06 III Result Thrombogenics (Belgium)   microplasmin Retinal disorders Europe and North America See details
2010-08-18 III Launch Clavis Pharma (Norway)   Elacytarabine (lipid-conjugated derivative of cytarabine developed using Clavis' lipid vector technology) The has been granted orphan drug status for the treatment of acute myeloid leukemia in the US and EU. acute myeloid leukemia USA and Europe See details
2010-08-11 I-IIa Launch Algeta (Norway)   Alpharadin® (radium-223 chloride - first-in-class alpha-pharmaceutical) Prostate cancer USA (Memorial Sloan-Kettering Cancer Center in New York and up to nine other centers in the USA) See details
2010-08-10 II Result Genmab (Denmark)   Arzerra® (ofatumumab) relapsed Diffuse Large B-Cell Lymphoma (DLBCL)   See details
2010-08-09 III Result Genmab (Denmark) GSK (UK) Arzerra® (ofatumumab) fludarabine and alemtuzumab refractory chronic lymphocytic leukemia   See details
2010-08-06 I Launch Galapagos (Belgium)   GLPG0634 (JAK inhibitor) This orally-available, novel candidate drug is selective against Janus kinase (JAK) 1 and 2 targets discovered in collaboration with GSK. The product was formally part of their arthritis alliance. Galapagos re-acquired the rights to GLPG0634 from GSK for an undisclosed amount and will initiate clinical development of this candidate without any further involvement from GSK. arthritis Belgium See details
2010-08-06 II Launch Clavis Pharma (Norway)   CP-4126 (lipid-conjugated derivative of gemcitabine, developed using Clavis' lipid vector technology) pancreatic cancer   See details
2010-08-04 I Launch Glycotope (Germany)   CetuGEX™ (GT-MAB 5.2-GEX) Various solid cancers Germany, Italy See details
2010-08-02 I Launch MorphoSys (Germany) Novartis (Switzerland) Undisclosed HuCAL-derived, fully human antibody Ophtalmology area   See details
2010-07-23 I Launch Genticel (France)   ProCervix® The vaccine is composed of two recombinant Adenylate Cyclase proteins (CyaA) in equal parts. Prevention of cervical cancer in patients already infected with human papillomavirus (HPV) Belgium See details
2010-07-17 II Launch BiondVax Pharmaceuticals (Israel)   multimeric-001 vaccine (universal influenza vaccine) influenza Israel See details
2010-07-12 I-IIa Result Biogen Idec (USA) Swedish Orphan Biovitrum (Sweden)   Long-acting recombinant factor IX Fc fusion protein (rFIXFc) hemophilia B   See details
2010-07-12 II Launch Transgene (France)   TG4040 (MVA-HCV, MVA virus carrying and expressing non structural proteins (NS3, NS4 et NS5B) of the hepatitis C virus) Hepatitis C Europe, USA and Israel See details
1   |   2   |   3   |   4   |   5   |   6   |   7   |   8   |   9   |   10   |   11      »      [57]